ROIV
Roivant Sciences (ROIV) Q2 2026 Earnings Call Transcript
Roivant Sciences (NASDAQ: ROIV) Q2 2026 Earnings Call dated Feb. 06, 2026 Corporate Participants: Stephanie Lee Griffin — Chief Operating…
Roivant Sciences (ROIV) Sec Form 8K
Roivant Sciences (NASDAQ: ROIV) Sec Form 8K
Roivant Sciences (ROIV) Sec Form 8K
Roivant Sciences (NASDAQ: ROIV) Sec Form 8K
Roivant Sciences (ROIV) Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
Roivant Sciences (NASDAQ: ROIV) FY 2026 Other Release
Roivant Sciences (ROIV) Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Roivant Sciences (NASDAQ: ROIV) FY 2026 Other Release
Roivant Sciences (ROIV) Sec Form 10Q
Roivant Sciences (NASDAQ: ROIV) Sec Form 10Q
Roivant Sciences (ROIV) Sec Form 8K
Roivant Sciences (NASDAQ: ROIV) Sec Form 8K
Roivant Reports Q3 Results, Cites Phase 2 Breakthrough and Catalyst-Rich 2026
Roivant Sciences (Nasdaq: ROIV) reported its financial results for the fiscal third quarter ended December 31, 2025, underscored by positive…
Roivant Sciences (ROIV) Q2 2026 Earnings Call
Roivant Sciences (NASDAQ: ROIV) Q2 2026 Earnings Conference